FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody that binds to BCMA. Also a nucleic acid encoding the said antibody; a vector and a host cell expressing the said antibody; immunoconjugate and chimeric antigen receptor containing the specified antibody; a nucleic acid encoding the said chimeric receptor; a vector containing the said nucleic acid; a virus containing the said vector; an immune cell containing the said nucleic acid, and either vector or virus are disclosed. The use of the said antibody for the production of a medicinal product, a conjugate, a multifunctional antibody, a tumor diagnostic agent, an immune cell; the use of the specified immunoconjugate for the production of a medicinal product, an agent for the diagnosis of a tumor, an immune cell; using the said immune cell to produce a medicinal product are disclosed.
EFFECT: invention makes it possible to effectively treat diseases associated with BCMA expression.
43 cl, 16 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, WHICH SPECIFICALLY BINDS TO BCMA, AND USE THEREOF | 2022 |
|
RU2820350C2 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
